Hikma Pharmaceuticals Trusted to deliver better health Our operations About Hikma Hikma Pharmaceuticals PLC (”Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) is a fast growing multinational pharmaceutical group which was founded in 1978 in Jordan 27 manufacturing facilities in 11 countries - FDA approved facilities in 5 countries Cost effective R&D and manufacturing Hikma develops, manufactures and markets a broad range of both branded and non-branded generic and in-licensed products Ribosepharm GmbH, Germany Thymoorgan GmbH, Germany Hikma is committed to the highest quality manufacturing with multiple FDA approved facilities Hikma Farmaceutica, Portugal Hikma Italia West-ward USA Hikma Pharmaceuticals, Jordan Hikma Chemicals, Jordan Hikma Pharma Algeria APM*, Jordan Ibn Al Baytar , Hikma Tunisia JPI* Saudi Arabia Promopham Morocco Hikma Pharma Egypt Pharmaland Pharmaceuticals, Sudan Hikma operates in the US, Europe and across the MENA region EPCI, Egypt Growth in MENA is driven by strong demographics and growing investment in healthcare Hikma Markets *JPI refers to Jazeera Pharmaceuticals Industries *APM refers to Arab Pharmaceutical Manufacturing *EPCI: Egyption Company for Pharmaceuticals & Chemical Industries Hikma delivered 23% revenue growth, underlying its strong financial record in 2013 Hikma is the fourth listed pharmaceutical company in the FTSE 250 R&D Centres Manufacturing Plants Financial highlights As of Dec. 2013, Hikma’s global team was made up of 7,067 employees 1400 1,365 Our track record 1300 Group revenues ($ million) 1200 1100 1,108.7 1000 918 $m 2013 2012 Revenue 1,365 1,108.7 Adjusted operating profit 412 193.8 Adjusted profit attributable to shareholders 274 120.5 107.6 51.1 20 16 900 800 730.9 700 637 581 600 500 400 317 300 200 100 0 Earnings per share (basic) (c) 449 51 67 76 99 90 105 138 188 212 262 Dividend per share (c) 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Our shares Primary listing London Stock Exchange (HIK) NASDAQ Dubai (HIK); 1 GDR=2 Ordinary Secondary listings OTC (HIK): 1 ADR=2 Ordinary Market cap £3.3 billion ($5.4 billion)* Reporting currency US Dollars ($) Free float 71% (90% institutional investors) *Based on 1st April closing price of £16.74 and an issued share capital of around 198.2 million ordinary shares as of 1st April 2014 Business development enquiries: Osama Nabulsi VP Business Development and Alliance Management Hikma Pharmaceuticals P.O. Box 182400 Amman 11118, Jordan [email protected] Investor & general enquiries: Susan Ringdal VP Corporate Strategy and Investor Relations Hikma Pharmaceuticals 13 Hanover Square London W1S 1HW, UK [email protected] Date: April 2014 Website: www.hikma.com Hikma Pharmaceuticals Trusted to deliver better health Our businesses Branded Our strategy for growth Products Markets 241branded branded 499 products MENA: Actos® ® MENA key Amoclan ® Blopress markets Amoclan ® ® Omnicef Jordan, Ciprolon ® ® Algeria, Saudi Suprax Prograf ® ® Arabia Votrex® Prograf 33 in-licensed products Top products Injectables 200 81 injectables injectable products MENA Argatroban MENA, Europe, Cefizox US Cefuroxime Europe Fentanyl Ciprolon US Iron gluconate 7 patented under Samixon Phenylephrine license products Vancomycin Robaxin Generics non branded 1147non --branded products US 2013 Revenue $320.8 $554 mm Strengthen our leading position in the MENA region Develop our global product range in growing therapeutic areas $149.3 $536 mm Extend our reach and diversity as partner of choice in the MENA region Increase the scale of our speciality Injectables business Amoxicillin Amoxicillin $105.7 $268 mm Cephalexin Cefaclor Doxycycline Doxycycline Methocarbamol Lisinopril Prednisone Lithium Carbonate Leverage our expertise and capacity in the US market Build on our world-class manufacturing and API sourcing capabilities Our strong performance in growing therapeutic areas in MENA Overall Oncology market $1.3 billion Hikma has launched 10 key products, and is developing a strong product pipeline Overall CNS market $1.14 billion Hikma CNS is growing 5 times as much as MENA CNS market with 10 major brands Overall CVD market $ 1.71 billion 6th largest supplier of cardiovascular and diabetes products by value Our partnerships More than 1800 sales representatives across MENA NYCOMED Partner of choice in the MENA region Reputation for quality products and long standing relationships with global licensing partners Mitsubishi Tanabe Pharma Strong brand recognition and experienced marketing teams with strong customer loyalty Excellent knowledge of registration processes and local health authorities Business development enquiries: Osama Nabulsi VP Business Development and Alliance Management Hikma Pharmaceuticals P.O. Box 182400 Amman 11118, Jordan [email protected] Teikoku Pharma USA, Inc. Investor & general enquiries: Susan Ringdal VP Corporate Strategy and Investor Relations Hikma Pharmaceuticals 13 Hanover Square London W1S 1HW, UK [email protected] Date: April 2014 Website: www.hikma.com
© Copyright 2024 ExpyDoc
